Could a Gut-Focused drug revive immunotherapy for tough melanomas?
Disease control
Not yet recruiting
This study tests whether adding axelopran, a drug that blocks opioid side effects in the gut, to the immunotherapy nivolumab can help people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial includes about 28 adults with unresectable or metastatic cutan…
Phase: PHASE1, PHASE2 • Sponsor: John Kirkwood • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC